Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.43 |
| ▸ | ULK1 | O75385 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.38 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.38 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3133570 | 0.94 | TLR7 (0.49) | TLR7LMNAHTTPAK1ULK1 | |
| SCHEMBL1803029 | 0.80 | LMNA (0.47) | LMNAHTTPAK1PKMHSD17B10 | |
| SCHEMBL3136748 | 0.80 | LMNA (0.58) | TLR7LMNAHTTPAK1PKM | |
| SCHEMBL7621597 | 0.78 | CHUK (0.50) | LMNAHTTPAK1PKMHSD17B10 | |
| SCHEMBL16146181 | 0.78 | LMNA (0.46) | LMNAHTTPAK1PKMHSD17B10 | |
| SCHEMBL12282148 | 0.78 | LMNA (0.46) | LMNAHTTPAK1PKMHSD17B10 | |
| SCHEMBL14183781 | 0.78 | KMT2A (0.49) | LMNAHTTPAK1PKMHSD17B10 | |
| SCHEMBL16146752 | 0.77 | LMNA (0.47) | LMNAHTTPAK1PKMHSD17B10 | |
| SCHEMBL5442344 | 0.77 | KMT2A (0.51) | LMNAHTTPAK1PKMHSD17B10 | |
| SCHEMBL183228 | 0.77 | KMT2A (0.51) | LMNAHTTPAK1PKMHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010020-A1 | PHOSPHODIESTERASE 4 INHIBITORS | LIU RUIPING | 2010-01-14 | — | — | US | disclosed |
| US-20100004236-A1 | PHOSPHODIESTERASE 4 INHIBITORS | TEHIM ASHOK | 2010-01-07 | — | — | US | disclosed |
| US-20080139583-A1 | PHOSPHODIESTERASE 4 INHIBITORS | TEHIM ASHOK | 2008-06-12 | — | — | US | disclosed |
| US-20080119495-A1 | PHOSPHODIESTERASE 4 INHIBITORS | LIU RUIPING | 2008-05-22 | — | — | US | disclosed |
| US-7342021-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2008-03-11 | — | — | US | disclosed |
| US-7332486-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070093510-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2007-04-26 | — | — | US | disclosed |
| EP-1529049-A2 | DERIVATIVES OF 2-TRIFLUORMETHYL-6-AMINOPURINE AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2005-05-11 | — | — | EP | disclosed |
| US-20040242598-A1 | Phosphodiesterase 4 inhibitors | LIU RUIPING (US) | 2004-12-02 | — | — | US | disclosed |
| WO-2004014913-A2 | DERIVATIVES OF 2-TRIFLUORMETHYL-6-AMINOPURINE AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-02-19 | — | — | WO | disclosed |
| EP-1383767-A1 | TRIFLUOROMETHYLPURINES AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20030045533-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. | 2003-03-06 | — | — | US | disclosed |
| WO-2002098878-A1 | TRIFLUOROMETHYLPURINES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093510-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3B, PDE3A | TLR7 4771/4885LMNA 3793/4885HTT 4634/4885 |
| US-20080139583-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | TLR7 4771/4885LMNA 3793/4885HTT 4634/4885 |
| US-20030045533-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3A, PDE3B | TLR7 4751/4885LMNA 4029/4885HTT 4684/4885 |
| US-20100004236-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | TLR7 4771/4885LMNA 3793/4885HTT 4634/4885 |
| US-20040242598-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3A, PDE3B | TLR7 4751/4885LMNA 4029/4885HTT 4684/4885 |
| US-20080119495-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | TLR7 4771/4885LMNA 3793/4885HTT 4634/4885 |
| US-20100010020-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | TLR7 4771/4885LMNA 3793/4885HTT 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.